Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYNORAL vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Contraception (prevention of pregnancy),Endometriosis (off-label use for pain management),Dysfunctional uterine bleeding (off-label),Menstrual suppression (off-label),Hormone replacement therapy component (off-label)
Prevention of pregnancy
50 mg orally three times daily
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life: 12–15 hours (11.2 ± 2.6 h in young adults; 14.8 ± 3.9 h in elderly), requiring once-daily dosing for steady-state within 4–7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes, forming conjugated metabolites (glucuronides and sulfates) that are excreted renally and fecally.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: ~50% as unchanged drug; ~20% as glucuronide conjugates. Biliary/fecal: ~30% (including enterohepatic recirculation).
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
97–99% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.8–1.0 L/kg (indicating extensive extravascular distribution, with significant tissue binding).
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 65–75% (due to first-pass hepatic metabolism; Tmax 2–4 hours).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
GFR 30-50 m L/min: 50 mg twice daily; GFR 15-29 m L/min: 50 mg once daily; GFR <15 m L/min: not recommended
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh class A: no adjustment; class B: 50 mg twice daily; class C: not recommended
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
2 mg/kg/dose orally three times daily; maximum 50 mg per dose
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Initiate at 25 mg twice daily; titrate slowly based on tolerance and renal function
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
LYNORAL carries a boxed warning for increased risk of thromboembolic disorders, including deep vein thrombosis and pulmonary embolism, especially in women with predisposing factors. Use is contraindicated in women with a history of or active thromboembolic disease.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thromboembolic risk: Discontinue if signs of thrombosis occur.,Bone mineral density loss: Long-term use may decrease BMD; consider calcium/vitamin D supplementation.,Hepatic impairment: Use with caution in patients with liver disease; monitor liver function.,Breakthrough bleeding: May occur, especially in the first months of use.,Depression: Monitor for mood changes; discontinue if severe depression develops.,Cardiovascular effects: May increase risk of hypertension and lipid profile changes.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Active or history of thromboembolic disorders (e.g., DVT, PE),Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Current or history of breast cancer (hormone-sensitive),Severe hepatic impairment or liver tumors,Hypersensitivity to LYNNORAL or any component
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Grapefruit juice may increase ethinylestradiol levels by inhibiting CYP3A4. Avoid excessive grapefruit consumption. St. John's Wort decreases effectiveness. No other significant food interactions.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Lynoral (ethinyl estradiol) is contraindicated in pregnancy due to significant teratogenic risk. First trimester exposure increases risk of cardiovascular defects, neural tube defects, and limb reduction anomalies. Second and third trimester exposure may cause fetal feminization in males, urogenital abnormalities, and potential long-term reproductive tract effects. Use only after confirmed absence of pregnancy.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Ethinyl estradiol is excreted into breast milk with an M/P ratio of approximately 0.37 to 0.50. It may reduce milk production and composition, and expose the infant to estrogenic effects. Use during lactation is generally not recommended; alternative contraception is preferred.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Lynoral is contraindicated in pregnancy; no dose adjustments are applicable. Pharmacokinetic changes such as increased clearance and volume of distribution occur in pregnancy, but the drug should not be used. If inadvertent exposure occurs, immediate discontinuation is required.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Lynoral (ethinylestradiol) is a potent estrogen used primarily in oral contraceptives and hormone therapy. Monitor for thromboembolic events, especially in smokers over 35. Prescribe the lowest effective dose. Assess liver function periodically due to hepatic metabolism. Use with caution in patients with migraine with aura, hypertension, or history of cholestasis. Discontinue 4 weeks prior to elective surgery to reduce thrombotic risk.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take at the same time daily to maintain consistent hormone levels.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially over age 35.,Report symptoms of blood clots: leg pain/swelling, sudden chest pain, difficulty breathing, or vision changes.,May cause nausea; taking with food can help.,Antibiotics (e.g., rifampin) and certain anticonvulsants may reduce effectiveness; use additional contraception.,Do not use during pregnancy; if pregnancy is suspected, discontinue and consult doctor.,Regular blood pressure monitoring is recommended.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYNORAL vs ALYACEN 1/35, answered by our medical review team.
LYNORAL is a Oral contraceptive that works by LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYNORAL and ALYACEN 1/35 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYNORAL is: 50 mg orally three times daily. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYNORAL and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYNORAL is classified as Category C. Lynoral (ethinyl estradiol) is contraindicated in pregnancy due to significant teratogenic risk. First trimester exposure increases risk of cardiovascular defects, neural tube defe. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.